R&D Changing Faces: Pharma and biotech, February 2026 The pharmaceutical and biotech sectors have seen a flurry of executive movement this month.
News Ipsen appoints Michelle Werner as North America head Ipsen has appointed biopharma industry veteran Michelle Werner, who recently stepped down as CEO of Alltrna, to lead its North America division.
News Lundbeck names AI head in quest to become 'bionic' company Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.
News Changes at the top of Sarepta, Alkermes, as CEOs depart Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.
News Ex-Novartis CMO John Tsai joins Daiichi Sankyo Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.
News NIH Director Bhattacharya will temporarily run CDC The long months without stable leadership at the CDC in the US look set to continue, as NIH chief Jay Bhattacharya is named acting director.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.